Preview

Epilepsy and paroxysmal conditions

Advanced search

THE COMPARATIVE EFFICACY OF PERSONALIZING THERAPY WITH ANTICONVULSANTS AND ANTIPSYCHOTICS ON THE BASIS OF PHARMACOGENETIC TESTING

https://doi.org/10.17749/2077-8333.2016.8.2.006-013

Full Text:

Abstract

The purpose of research — to develop a pharmacogenetic test to predict the speed and features of a metabolism of anticonvulsants, antipsychotics, antidepressants, depending on genetically determined activity of enzyme systems and proteins-transporters of drugs.

Materials and Methods. During 4 years in the study included 260 patients with epilepsy and schizophrenia, located on the hospital treatment in the Centre of Mental Health (Minsk). Patients characterized by the presence of side effects and drug-resistance.

Results. As a result, taking into account the genetic information in 79% of patients with epilepsy and in 73% of patients with schizophrenia, there was a significant clinical effect.

Conclusion. The results demonstrated the great significance of pharmacokinetic and pharmacodynamic characteristics of the particular patient in the development of pharmacoresistance, regardless of nosology. The genetics of drug metabolism can improve the treatment and reduce the time to achieve clinical benefit from the treatment.

About the Authors

T. V. Dokukina
Republican Scientific and Practical Center for Mental Health
Belarus

MD, Phd, deputy director for scientific work,

Dolginovskii trakt, 152, Minsk, 220053



A. I. Startsev
Republican Scientific and Practical Center for Mental Health
Belarus

Director,

Dolginovskii trakt, 152, Minsk, 220053



M. V. Makhrov
Republican Scientific and Practical Center for Mental Health
Belarus

Researcher at the Department of Mental and Behavioural Disorders,

Dolginovskii trakt, 152, Minsk, 220053



I. V. Haidukevich
Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus
Belarus

Researcher at the Laboratory of Molecular Diagnostics and Biotechnology,

V. F. Kuprevicha str., 5/2, Minsk, 220141



T. S. Golubeva
Republican Scientific and Practical Center for Mental Health
Belarus

PhD, Leading Researcher at the Department of Mental and Behavioural Disorders,

Dolginovskii trakt, 152, Minsk, 220053



A. A. Gilep
Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus
Belarus

PhD, Head of the Laboratory of Molecular Diagnostics and Biotechnology,

V. F. Kuprevicha str., 5/2, Minsk, 220141



E. A. Sheremet
Republican Scientific and Practical Center for Mental Health
Belarus

Researcher at the Department of Mental and Behavioural Disorders,

Dolginovskii trakt, 152, Minsk, 220053



I. V. Shamruk
Republican Scientific and Practical Center for Mental Health
Belarus

Researcher at the Department of Mental and Behavioural Disorders,

Dolginovskii trakt, 152, Minsk, 220053



A. S. Pinchuk
Republican Scientific and Practical Center for Mental Health
Belarus

Researcher at the Department of Mental and Behavioural Disorders,

Dolginovskii trakt, 152, Minsk, 220053



S. A. Marchuk
Republican Scientific and Practical Center for Mental Health
Belarus

Researcher at the Department of Mental and Behavioural Disorders,

Dolginovskii trakt, 152, Minsk, 220053



F. P. Khlebokazov
Republican Scientific and Practical Center for Mental Health
Belarus

PhD, Head of the Department for the treatment of psychiatric disorders due to epilepsy,

Dolginovskii trakt, 152, Minsk, 220053



N. N. Misyuk
Republican Scientific and Practical Center for Mental Health
Belarus

PhD, Doctor of functional diagnostics,

Dolginovskii trakt, 152, Minsk, 220053



References

1. Blinov D.V. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / Pharmacoeconomics . Modern pharmacoeconomics and pharmacoepidemiology. 2014; 7 (1): 40-45.

2. Gaikovaya L.B., Burbello A. T., Ermakov A. I., Fedorenko A.S., Vavilova T.V., Komok M.V. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / Pharmacoeconomics . Modern pharmacoeconomics and pharmacoepidemiology. 2014; 7 (1): 9-13.

3. Dokukina T.V., Makhrov M.V., Gaidukevich I.V., Gilep A.A., Golubeva T.S., Khlebokazov F.P., Misyuk N.N., Korolevich P.P. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2015; 4: 22-28.

4. Dokukina T.V., Golubeva T.S., Matveichuk I.V., Makhrov M.V., Loseva V.M., Krupen’kina E.V., Marchuk S.A. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / Pharmacoeconomics . Modern pharmacoeconomics and pharmacoepidemiology. 2014; 7 (2): 33-37.

5. Kantemirova B. I., Starodubtsev A.K., Sychev D.A., Belopasov V.V., Tsotsonava Zh.M., Griganov V. I. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2012; 3: 14-18.

6. Kukes V.G., Sychev D.A., Ramenskaya G.V., Ignat’ev I.V. Biomeditsina. 2007; 6: 29-47.

7. Mikhailov V.A. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2010; 3: 39-44.

8. Semakina N.V., Mikhailov V.A., Bagaev V. I. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2013; 1: 31-37.

9. Sychev D.A. Farmakogeneticheskie testirovanie: klinicheskaya interpretatsiya rezul’tatov. 2011; M. 83 c.

10. Chukanova A.S., Tushkanov M.A., Barskii V. I., Grazhdan I.K., Krikova E.V., Aksenova M.G., Burd S.G., Gusev E. I. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2011; 2: 45-54.

11. Shal’kevich L.V., Smychek V.B., Kudlach A. I. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2015; 3: 26-31.

12. Delozier T.S., Kissling G. E., Coulter S. J., Dai D., Foley J. F., Bradbury J.A., Murphy E., Steenbergen C., Zeldin D.C., Goldstein J.A. Detection of human CYP2C8, CYP2C9 and CYP2J2 in cardiovascular tissues. Drug Metab Dispos. 1999; 35: 682-688.

13. Eichelbaum M., Ingelman-Sundberg M., Evans W. E. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006; 57: 119-37.

14. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmöller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., Brinkmann U. Functional polymorphisms of the human multidrugresistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000 Mar 28; 97 (7): 3473-8.

15. Ingelman-Sundberg M., Sim S.C. Pharmacogenetic biomarkers as tools for improved drug therapy: Emphasis on the cytochrome P450 system. Biochem Biophys Res Commun. 2010; 396: 90-4.

16. Kirchheiner J., Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophy Acta. 2007; 1770 (3): 489-94.

17. Klose T.S., Blaisdell J.A., Goldstein J.A. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol. 1999; 13 (6): 289-95.

18. Li Y.H., Wang Y.H., Li Y., Yang L. MDR1 gene polymorphisms and clinical relevance. Yi Chuan Xue Bao. 2006; 33: 93-104.

19. Van der Weide J., Hinrichs J.W. The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. Clin. Biochem. Rev. 2006; 27 (1): 17-25.


For citation:


Dokukina T.V., Startsev A.I., Makhrov M.V., Haidukevich I.V., Golubeva T.S., Gilep A.A., Sheremet E.A., Shamruk I.V., Pinchuk A.S., Marchuk S.A., Khlebokazov F.P., Misyuk N.N. THE COMPARATIVE EFFICACY OF PERSONALIZING THERAPY WITH ANTICONVULSANTS AND ANTIPSYCHOTICS ON THE BASIS OF PHARMACOGENETIC TESTING. Epilepsy and paroxysmal conditions. 2016;8(2):6-13. (In Russ.) https://doi.org/10.17749/2077-8333.2016.8.2.006-013

Views: 241


ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)